novel therapeutics
Development and novel therapeutics in hepatocellular carcinoma: a review
... current novel therapeutics, including the drugs under clinical trials, and future therapeutic trends for hepatocellular carcinoma ...pursuing novel therapeutic targets as well as predictive biomarker ...
11
Novel therapeutics: response and resistance in ovarian cancer
... 'Novel Therapeutics' session were reviewed and are summarized ...of novel agents, including poly-ADP-ribose polymerase (PARP) inhibitors, other DNA-damaging agents, vascular endothelial growth factor ...
6
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
... evaluated after approval. We found that when post- approval trials do evaluate surrogate markers, the treat- ment effects are smaller in comparison to the treatment effects observed among pivotal trials using the same ...
14
Novel therapeutics for coronary artery disease from genome-wide association study data
... Background: Coronary artery disease (CAD), one of the leading causes of death globally, is influenced by both environmental and genetic risk factors. Gene-centric genome-wide association studies (GWAS) involving cases ...
11
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
... circulating cell free DNA evaluating tumor clone response to molecularly targeted drug. 497 [r] ...
41
Identification of novel therapeutics for complex diseases from genome-wide association data
... potential novel drug targets among the predicted candidate genes by associating drug information extracted from publicly available drug ...identify therapeutics for treatment of specific complex diseases ...
14
Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics
... pathogens, novel therapeu- tics are focusing on alternative ways of disarming pathogens, such as interfering with quorum-sensing and secretion sys- tems, inhibiting toxin production and diffusion, and limiting the ...
9
Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
... therapeutic indications including T-DM1 as first-line therapy in the metastatic and adjuvant settings. Other combinations of mAbs, or mAbs and TKIs, have been completed or are underway evaluating potential more effective ...
10
A Decoy Receptor Approach Using Nicotinic Acetylcholine Receptor Mimics Reveals Their Potential as Novel Therapeutics Against Neurotoxic Snakebite
... a novel class of snake-generic therapeutics for combatting neurotoxic ...adjunct therapeutics for improving the safety and affordability of existing snakebite treatments by reducing therapeutic ...
15
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer
... Spautin-1 acts as an inhibitor of ubiquitin-specific peptidase 10 (USP10) and USP13 via promoting the degradation of Vps34, and has been documented as an autophagy inhibitor [16]. Subsequent studies showed that Spautin-1 ...
16
QUORUM QUENCHERS – PAST, PRESENT AND FUTURE OF THIS NOVEL THERAPEUTICS.
... One of the significant developments of modern medicine is the discovery and development of antibiotics to treat infectious diseases. The treatments by using antimicrobial agents aim to bring either bacteriostatic or ...
21
“QUANTUM DOTS: AN OPTIMISTIC APPROACH TO NOVEL THERAPEUTICS” by S Mukherjee*, Ushasi Das, India.
... Nanotechnology is a multidisciplinary field and has achieved breakthroughs in bioengineering, molecular biology, diagnostics, and therapeutics. Targeted delivery of therapeutic agents has the potential to localize ...
6
Translating the biology of aging into novel therapeutics for Alzheimer disease
... Biological aging is the leading risk factor for the major de- bilitating chronic diseases of old age that cause morbidity and Table 4 Neuroprotective interventions that are in clinical d[r] ...
11
Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U S Food and Drug Administration approvals
... all novel therapeutics (i.e., new molecular entities—- drugs—and novel biologics) that were approved by the FDA between 1 January 2011 and 31 December 2013 ...the novel therapeutics ...
11
CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential
... of novel anti-cancer chemokine-based therapeutics (25, 70, ...for novel therapeutics for this devastating disease it is tempting to speculate that CXCR4 antagonists will join in the near ...
8
Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics
... CTAB has also been assessed for anti-cancer activity in the National Cancer Institute Developmental Therapeutics Program (<www.dtp.nci.nih.gov>) in mouse cancer models of lymphocytic leukemia (P388 and ...
15
Synthesis And Evaluation Of Novel Tropane Compounds As Potential Therapeutics For Drug Abuse
... In the last decade, a lot of research was focused on synthesizing only dopamine transporter selective compounds, which ultimately did not provide a viable therapeutic for drug abuse. However, now it is well established ...
145
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics
... Although dietary, genetic, or disease-related excesses in urate production may contribute to hyperuricemia, impaired renal excretion of uric acid is the dominant cause of hyperuricemia in the majority of patients with ...
9
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody Enhanced Dengue Virus Infection
... 56. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitaya- sunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, ...
13
Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease
... observations that BuChE assumes a more important role in the AD brain during disease progression [8–10]. Another major theme has been the design of hybrids able to modulate simultaneously several aspects of the complex ...
11